Jonathan Burlison, Ph.D., is the Patient Safety Project manager in the Pharmaceutical Sciences Department at St. Jude Children’s Research Hospital.
A CRISPR screen reveals a potential combination therapy for relapsed neuroblastoma.
St. Jude Global helps provide a framework for rebuilding health care capacity after a crisis.
Explore how tumor-associated macrophages shape CAR T-cell therapy efficacy in high-grade gliomas.
Discover how disruption ribosomes creation provides promise for “undruggable” cancers.
See how Aseem Ansari's SynGRs target BET proteins, offering potential for treating diseases like Friedreich’s ataxia and advancing BET domain understanding
Follow the path of illustrious speakers that have spoken at St. Jude’s keystone lecture series.